Am­gen to cut 350 staffers fol­low­ing $28B Hori­zon takeover

Last year
People
Pharma

Sanders goes af­ter NIH for grant­i­ng ex­clu­sive patent for po­ten­tial can­cer ther­a­py

Last year
Pharma
FDA+

Mer­ck KGaA rais­es aware­ness for smol­der­ing MS symp­toms that cause pa­tients to 'un­rav­el'

Last year
Pharma
Marketing

How No­vo Nordisk’s Ry­bel­sus went from pan­dem­ic washout to block­buster, and what’s next for oral weight loss

Last year
Pharma
Marketing

Mar­ket­ingRx roundup: Fishawack re­brands as Avalere Health; BMS, Gilead, Am­gen re­up clin­i­cal di­ver­si­ty pro­gram

Last year
Pharma
Marketing

Bris­tol My­ers pays $350M up­front for rights to heart drug Camzyos in Asia

Last year
Deals

Brain­Storm to lay off work­ers; Lil­ly inks a sub­cu­ta­neous deal

Last year
News Briefing

A hack­er leaked mil­lions of 23andMe users’ da­ta, and the leak of an­ces­try da­ta could have im­pli­ca­tions on sen­si­tive ...

Last year
Health Tech

Or­biMed rais­es $4.3B across three funds to in­vest in biotech com­pa­nies, as well as roy­al­ty deals and Chi­na star­tups

Last year
Financing

Im­mutep touts mid-stage da­ta for LAG-3 drug in first-line NSCLC, fi­nal­iz­ing plans for PhI­II test: #ES­MO23

Last year
R&D

Up­dat­ed: No­var­tis 'on track' to com­plete re­struc­tur­ing post San­doz spin, push­es back Plu­vic­to fil­ing

Last year
R&D
Pharma

Idor­sia lays off up to 300 peo­ple, plans for pipeline pri­or­i­ti­za­tion in ef­fort to ex­tend cash run­way

Last year
People
Pharma

Ram­part Bio­science rais­es $125M for non-vi­ral gene ther­a­pies

Last year
Financing
Startups

Aio­los Bio launch­es with $245M Se­ries A, chas­ing one of asth­ma’s hottest tar­gets

Last year
Financing
Startups

Heard at #ES­MO23: No­var­tis and BeiGene fall­out; Now I know my AD­Cs; and a stand­ing ova­tion

Last year
R&D

Sanofi and Re­gen­eron's block­buster Dupix­ent re­ject­ed by FDA for chron­ic hives con­di­tion

Last year
Pharma
FDA+

FDA ap­proves first sub­cu­ta­neous ver­sion of block­buster IBD drug in­flix­imab

Last year
Pharma
FDA+

Why is­n't Ver­tex de­clar­ing suc­cess for its non-opi­oid pain drug in a late-stage tri­al?

Last year
Pharma

Pe­di­atric la­bels: FDA ex­pands can­cer and dwarfism drugs from Genen­tech and Bio­Marin

Last year
Pharma
FDA+

Un­ap­proved us­es of ap­proved drugs: FDA lays out phar­ma con­sid­er­a­tions for in­form­ing providers

Last year
Pharma
FDA+

New Plu­vic­to da­ta point to a po­ten­tial wider in­di­ca­tion, but No­var­tis leaves reg­u­la­to­ry time­line up in the air: ...

Last year
R&D

BioN­Tech CAR-T man­u­fac­tur­ing change leads to fresh da­ta with vac­cine com­bo, with reg­is­tra­tional tri­al plans: #ES­MO23

Last year
R&D
Cell/Gene Tx

From Ap­ple to Lil­ly: Drug­mak­er's chief dig­i­tal of­fi­cer talks AI ex­per­i­ments and the GLP-1 cus­tomer ex­pe­ri­ence

Last year
Pharma
Health Tech

How J&J’s Ry­bre­vant com­bo stacks up against As­traZeneca’s Tagris­so in EGFR-mu­tat­ed lung can­cer: #ES­MO23

Last year
R&D
First page Previous page 258259260261262263264 Next page Last page
A service from the Financial Times